2005, a pivotal year for Axis-Shield, with strong growth and profitability

I noticed a few months ago that Bionostics had received FDA clearance for the NycoCard control, which I recently confirmed with ASD that the rationale was an improved control on improved terms/costs to ASD. Which I guess in turn affects the freeing up further manufacturing capacity at ASD, cue assay’s for Axsym. -



High homocysteine tied to memory loss
Tue Dec 20, 2005 9:17 PM GMT -